MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

Search

Sanofi SA

Închisă

SectorSănătate

88.23 0.88

Rezumat

Modificarea prețului

24h

Curent

Minim

87.47

Maxim

88.42

Indicatori cheie

By Trading Economics

Venit

1.4B

1.9B

Vânzări

3B

11B

P/E

Medie Sector

17.216

51.198

EPS

1.79

Randament dividend

4.48

Marjă de profit

17.65

Angajați

82,878

EBITDA

2.2B

2.8B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+31.16% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.48%

2.40%

Următoarele câștiguri

31 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-19B

111B

Deschiderea anterioară

87.35

Închiderea anterioară

88.23

Sentimentul știrilor

By Acuity

39%

61%

136 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Sanofi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 iun. 2025, 16:05 UTC

Principalele dinamici ale pieței

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2 iun. 2025, 09:17 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 iun. 2025, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22 mai 2025, 12:02 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22 mai 2025, 00:06 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Vigil Neuroscience for About $470 Million

2 iun. 2025, 13:50 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 iun. 2025, 12:33 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2 iun. 2025, 10:50 UTC

Achiziții, Fuziuni, Preluări

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 iun. 2025, 10:05 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 iun. 2025, 05:06 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 iun. 2025, 05:06 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 iun. 2025, 05:05 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 iun. 2025, 05:05 UTC

Achiziții, Fuziuni, Preluări

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 iun. 2025, 05:04 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 iun. 2025, 05:04 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 iun. 2025, 05:03 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Blueprint Medicines Corporation

2 iun. 2025, 05:02 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Acquire Blueprint Medicines Corporation

30 mai 2025, 08:58 UTC

Acțiuni populare

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 mai 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27 mai 2025, 05:03 UTC

Achiziții, Fuziuni, Preluări

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27 mai 2025, 05:00 UTC

Achiziții, Fuziuni, Preluări

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21 mai 2025, 23:33 UTC

Achiziții, Fuziuni, Preluări

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mai 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mai 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mai 2025, 23:23 UTC

Achiziții, Fuziuni, Preluări

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mai 2025, 23:22 UTC

Achiziții, Fuziuni, Preluări

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mai 2025, 23:20 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mai 2025, 23:18 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

19 mai 2025, 11:01 UTC

Market Talk

Diversified Exposure to European Banks Is Required -- Market Talk

15 mai 2025, 11:04 UTC

Market Talk
Câștiguri

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

Comparație

Modificare preț

Sanofi SA Așteptări

Obiectiv de preț

By TipRanks

31.16% sus

Prognoză pe 12 luni

Medie 114.266 EUR  31.16%

Maxim 127 EUR

Minim 95 EUR

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSanofi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

12

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

91.3 / 96.1Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

136 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.